



2021 ANNUAL REPORT

**GLOBAL
HEALTHCARE**
DIVIDEND FUND



MIDDLEFIELD MUTUAL FUNDS

MIDDLEFIELD CORPORATE PROFILE

The Middlefield Group was established in 1979 and is a Specialty Investment Manager which creates investment products designed to balance risk and return to meet the demanding requirements of Financial Advisors and their clients. These financial products include Exchange-Traded Funds, Mutual Funds, Private and Public Resource Funds, Split Share Corporations, Venture Capital Assets, TSX Publicly Traded Funds and Real Estate Investment Funds and Partnerships.

Middlefield's investment team comprises portfolio managers, analysts and traders. While all of our investment products are designed and managed by Middlefield professionals, some involve strategic partnerships with other "best-in-class" firms that bring unique value to our product offerings. In 2014, we entered into an exclusive arrangement with SSR, LLC, based in Stamford, Connecticut. They provide specialized research into sectors of the economy such as Healthcare and Innovation Technology. SSR is an independent investment firm whose analysts have been highly ranked and are recognized as leaders in their respective fields. Their fundamental company level research is often non-consensus and provides guidance on overall portfolio construction and security selection.

Looking ahead, Middlefield remains committed to managing and developing new and unique investment products to assist Financial Advisors in helping clients achieve their investment objectives.

TABLE OF CONTENTS

	Corporate Profile
2	2021 Review and Outlook
5	Annual Management Report of Fund Performance
11	Management's Responsibility for Financial Reporting
11	Independent Auditor's Report
13	Financial Statements
18	Notes to Financial Statements Middlefield Funds Family Corporate Information

A NOTE ON FORWARD LOOKING STATEMENTS

This document may contain forward looking statements, including statements regarding: the Fund, its strategies, goals and objectives; prospects; future performance or condition; possible future actions to be taken by the Fund; and the performance of investments, securities, issuers or industries in which the Fund may from time to time invest. Forward looking statements include statements that are predictive in nature, that depend upon or refer to future results, events, circumstances, expectations and performance, or that include words such as "expects", "anticipates", "intends", "plans", "believes", "estimates" or negative versions thereof and other similar wording. Forward looking statements are not historical facts, but reflect the Fund's current beliefs as of the date of this document regarding future results, events, circumstances, expectations or performance and are inherently subject to, among other things, risks, uncertainties and assumptions about the Fund and economic factors. Forward looking statements are not guarantees of future performance, and actual results, events, circumstances, expectations or performance could differ materially from those expressed or implied in any forward looking statements contained in this document. Factors which could cause actual results, events, circumstances, expectations or performance to differ materially from those expressed or implied in forward looking statements include, but are not limited to: general economic, political, market and business factors and conditions; commodity price fluctuations; interest and foreign exchange rate fluctuations; global equity and capital markets; the financial condition of each issuer in which the Fund invests; the effects of competition in the industries or geographic areas in which the Fund may invest; statutory and regulatory developments; unexpected judicial or regulatory proceedings; and catastrophic events. Readers are cautioned that the foregoing list of factors is not exhaustive and to avoid placing undue reliance on forward looking statements due to the inherent uncertainty of such statements. The Fund does not undertake, and specifically disclaims, any obligation to update or revise any forward looking statements, whether as a result of new information, future developments, or otherwise.



MIDDLEFIELD

Global Real Estate Class

FE/LL/DSC/Series F MID 600 | 649 | 650 | 601



**REFINITIV LIPPER
FUND AWARDS**

**2021 WINNER
CANADA**

Top-performing Real Estate Fund Over 5 Years

"Middlefield is very pleased to be recognized for its performance, especially given the unique challenges faced by the real estate sector in 2021. We are focused on selecting the highest quality companies who are best positioned to benefit from long term, durable trends in the real estate industry."



(L to R) ROB MOFFAT, Director, Investments and Portfolio Manager, NANCY THAM, Managing Director, Sales, JEREMY BRASSEUR, Executive Chairman, DEAN ORRICO, President and Chief Investment Officer, ROB LAUZON, Chief Investment Officer, POLLY TSE, Chief Financial Officer and SHANE OBATA, Executive Director, Investments and Portfolio Manager

To learn more about *Middlefield Funds*, speak with your financial advisor or contact us at:



Middlefield Funds
YOUR PARTNER IN INCOME & GROWTH

1-888-890-1868
invest@middlefield.com
www.middlefield.com

Toronto Office:
First Canadian Place
58th Floor, P.O. Box 192
Toronto, Ontario M5X 1A6

Calgary Office:
812 Memorial Drive NW
Calgary, Alberta T2N 3C8

The Refinitiv Lipper Fund Awards are based on the Lipper Leader for Consistent Return rating, which is a risk-adjusted performance measure calculated over 36, 60 and 120 months. Lipper Leaders fund ratings do not constitute and are not intended to constitute investment advice or an offer to sell or the solicitation of an offer to buy any security of any entity in any jurisdiction. For more information, see lipperfundawards.com. Refinitiv Lipper Fund Awards, ©2021 Refinitiv. All rights reserved. Used under license.

Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns including changes in share value and reinvestment of all distributions and does not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Investment fund are not guaranteed, their values change frequently and past performance may not be repeated.



2021 REVIEW AND OUTLOOK

Global equity markets performed extremely well in 2021. The TSX generated a total return of 25.2%, its best annual performance since 2009. The S&P 500 returned 28.7% and recorded 70 record highs throughout the year. Even more impressive is the 113% return the S&P 500 generated since it bottomed on March 23, 2020. The MSCI World Index generated a total return of 22.4%, slightly underperforming major North American indices due to weakness in Asian markets.

The market's demand for sustainable investing accelerated in 2021, which is designed to better understand the Environmental, Social, and Governance (ESG)-related risks and opportunities in a company. While traditional financial analysis remains core to our investment decisions, incorporating ESG data provides us with a more holistic view of the companies we invest in and also enhances our ability to determine which are more likely to achieve their long-term growth objectives. To support our capabilities in sustainable investing, Steve Erlichman joined Middlefield as Chair, ESG in 2021. Together with Steve, we have refreshed our ESG policy and have established Stewardship Principles which, among other things, guide how Middlefield monitors its portfolio companies and votes corporate proxies.

Elevated geopolitical tensions are contributing to supply chain disruptions, rising costs and increasing concern among investors. Despite the operational challenges, we believe the leading management teams will be able to mitigate the impact of inflation and supply chain bottlenecks. While it will likely take several quarters for these issues to resolve, corporations have demonstrated success in allocating capital more efficiently and in technologies which are enhancing productivity.

We are optimistic that the COVID-19 pandemic will gradually become endemic in 2022 as the economic reopening gains momentum with travel restrictions, vaccine requirements and mask mandates gradually being lifted in multiple jurisdictions. The OECD has forecasted GDP growth of 3.9% in Canada and 3.7% in the U.S. for 2022 – both well-above pre-pandemic trends.

Cyclical sectors such as financials and energy are expected to benefit the most from earnings tailwinds as the economy continues to recover from the COVID-19 pandemic. We are also constructive on quality growth businesses with predictable revenue and cash flow generation whose share prices have declined during late December 2021 and January 2022. Valuations for several high-quality growth industries have significantly corrected in recent weeks and we believe this represents an excellent entry point for select companies within the software, clean power and biotechnology sectors.

In terms of market risks, we are closely following the high levels of inflation and its derivative impacts on market fundamentals. Specifically, inflation is contributing to an accelerated withdrawal of monetary stimulus around the world as central banks begin to prioritize containing inflationary pressures. While the exact number and timing of rate hikes is not certain, it is clear that central banks around the world are on the cusp of a prolonged tightening cycle. The Bank of England has been the first major central bank to initiate liftoff, imposing back-to-back rate hikes for the first time since 2004. Jerome Powell, Chair of the FOMC, has recently stressed the strength of the U.S. labour market and reiterated the Fed's intention to use multiple tools to temper inflation. These tools are likely to include a runoff of Treasuries and mortgage backed securities from the Fed's balance sheet beginning in the latter half of 2022, an issue that is quickly growing in importance for investors. Similar to interest rate hikes, we believe the market will be able to absorb a balance sheet runoff as long as it is done at a gradual pace and is appropriately communicated. The Bank of Canada has signaled its hiking cycle is likely to begin at the March 2022 meeting but with inflation being lower in Canada and less upside to commodity prices than this time last year, we believe the Bank of Canada will likely remain less hawkish than its US counterpart.

Real estate investment trusts (REITs) provide an optimal solution against this backdrop and can serve as a useful tool to dampen the impacts of inflation and rising interest rates. This is due to the fact that real estate owners have the ability to pass on rising costs via higher rents and many leases also include inflation-linked escalators. Forward earnings growth for REITs is expected to be well above historical averages for several years, yet Canadian REITs still trade at a discount to their net asset values on average. Increasing cash flows from rising rental income also supports distribution growth, a core tenet of long-term investing. We expect many REITs to increase their distributions in 2022 which are taxed efficiently in Canada, making them an attractive source of stable and growing income.

The Middlefield Family of mutual funds, which are listed at the end of this report, currently includes eight different funds within the multi-class structure and three mutual fund trusts. The multi-class structure of Middlefield Mutual Funds enables investors to benefit from superior tax efficiencies unavailable to other forms of investment funds. In addition, almost all classes are offered in F-Series.

Middlefield Global Real Estate Class provides exposure to the global and Canadian real estate markets through an actively managed strategy and has consistently delivered attractive total returns over its 10+ year history. The Fund generated a total return of 35.8% in 2021, outperforming its benchmark and building upon its longstanding track record. The Series F shares of the Fund were recognized in 2021 by Refinitiv Lipper Fund Awards for the Best Five-Year Performance in the Real Estate Equity category. We expect REITs to generate solid performance in 2022 with operating metrics trending more positively as landlords recover from the pandemic.

Income Plus Class generated a total return of 30.9% in 2021, outperforming both the S&P 500 Index and S&P/TSX Composite Index. The Fund is focused on high quality issuers with stable cash flows and track records of growing dividends. Real estate and financials are both sectors that meet these criteria and finished 2021 as the top two sector weights in the portfolio. In addition to REITs, financials should continue with dividends bumps in 2022 and perform well against an inflationary backdrop. The forthcoming rate hiking cycle will also provide a significant profitability tailwind for the lending business of banks and other financial services, thus improving their net interest margins. Bank of Nova Scotia, a holding in the Fund, announced a dividend increase of 23% in November of 2021.

Global Infrastructure Fund generated a total return of 13.2%, lagging the broader market but outperforming the S&P Global Infrastructure Index which returned 11.9%. The asset class likely underperformed due to rising interest rate expectations and higher discount rates being applied to future cash flows. The Fund is focused on companies that have the ability to offset these risks and grow their cash flows over time. Utilities, the Fund's largest weighting, are a sector in which companies typically achieve a degree of inflation pass-through in rate negotiations with regulators. In light of the recovery in commodity prices, we also have a positive view on energy infrastructure companies that have exposure to the resurgence of capital investment in the energy sector. Enbridge Inc., a core holding in the Fund, benefits from both dynamics as it operates critical energy infrastructure assets that are in high demand as well as a premier North American utility franchise.

Global Healthcare Dividend Fund generated a total return of 19.0% in 2021. We are bullish on healthcare in 2022 and believe it is an excellent time to add exposure. Past headwinds for the biopharma industry, including drug pricing, regulatory uncertainty and lack of M&A, are gradually turning into tailwinds. The share prices of many innovative biotechnology companies have declined by more than 50% from recent highs while a number of large-cap incumbents are sitting on record amounts of cash. Medtech companies are also well-positioned to benefit from declining COVID-19 hospitalizations and pent-up demand for elective surgeries. The healthcare sector finished the year trading at a forward P/E multiple of just 17.3x, more than 4 turns cheaper than the S&P 500 multiple of 21.6x. In addition, Canadians are typically underexposed to healthcare which is the second largest sector in the S&P 500 behind Information technology.

Outlook

Although inflation is elevated and interest rates are rising, we expect a gradual easing of supply chain bottlenecks and labour shortages and expect management teams to continue to identify methods to employ new and innovative technologies to suppress rising costs. That said, with central bankers pivoting to tight from easy monetary policy and geopolitical tensions in Russia/Ukraine and Iran impacting already high oil and gas prices, market volatility is expected to remain high.

As a result, unlike 2021 where "a rising tide lifted all boats", we believe active management and careful stock selection are critical in the current market environment. In addition, investing in stable businesses with competent management teams should prove to be beneficial to performance. Rising interest rates are likely to have an outsized impact on companies with limited earnings visibility or excessive leverage. Our conviction lies in identifying the highest quality businesses who possess predictable streams of cash flow and healthy balance sheets. Dividend-paying and dividend-growing equities typically fit this description and will continue to form the foundation of Middlefield's portfolios.



Dean Orrico
President and CEO
Middlefield Capital Corporation



Robert F. Lauzon
Managing Director and Chief Investment Officer
Middlefield Capital Corporation

An Award-Winning Family of Mutual Funds

TRUST FUNDS

GLOBAL HEALTHCARE DIVIDEND FUND

[MID 325/327/330] Series F [MID 326]

The Fund's objectives are to provide stable cash distributions and long-term total returns. The Fund invests primarily in dividend paying securities of global issuers operating in, or deriving a significant portion of their revenue or earnings from, the healthcare industry.

INDEXPLUS INCOME FUND

[MID 435/437/440] Series F [MID 436]

The Fund's objectives are to pay monthly distributions and outperform the S&P/TSX Composite High Dividend Index. The Fund invests in a diversified portfolio of equity income securities of which a portion tracks the Index. The remainder of the portfolio is actively managed to enhance returns and reduce the risks associated with indexing, while maintaining low-cost exposure to the underlying equity income market.



4-STAR RATING (MORNINGSTAR)

MIDDLEFIELD GLOBAL INFRASTRUCTURE FUND

[MID 510/519/520] Series F [MID 501]

The Fund's objective is to maximize long-term total return by investing in a diversified portfolio of companies that own, develop, maintain or are involved in the global infrastructure sector.



4-STAR RATING (MORNINGSTAR)

CORPORATE CLASS FUNDS

MIDDLEFIELD INCOME PLUS CLASS

[MID 800/849/850] Series F [MID 801]

The objective of this Fund is to provide a stable level of income while emphasizing capital preservation by investing in a diversified portfolio of equity and fixed income securities. Income Plus Class received Fundata's FUNDGRADE® "A" Award for outstanding performance in the 2013 calendar year.



WINNER OF THE 2017
THOMSON REUTERS
LIPPER FUND AWARDS
CANADA



MIDDLEFIELD U.S. DIVIDEND GROWERS CLASS

[MID 710/719/720] Series F [MID 701]

The objective of this Fund is to maximize long-term total return by investing primarily in dividend paying equity and fixed income securities of U.S. issuers.

MIDDLEFIELD GLOBAL DIVIDEND GROWERS CLASS

[MID 181/183/186] Series F [MID 182]

The objective of this Fund is to maximize long-term total return by investing primarily in dividend paying equity and fixed income securities of global issuers.



4-STAR RATING (MORNINGSTAR)

MIDDLEFIELD GLOBAL REAL ESTATE CLASS

[MID 600/ 649/ 650] Series F [MID 601]

The Fund's objectives are to provide a stable level of income and maximize long-term total return. The Fund invests primarily in equities, including real estate investment trusts and common stocks, as well as equity-related and fixed income securities of issuers operating in the real estate sector.



5-STAR RATING (MORNINGSTAR)



REFINITIV LIPPER
FUND AWARDS
2021 WINNER
CANADA

MIDDLEFIELD CANADIAN DIVIDEND GROWERS CLASS

[MID 148/449/450] Series F [MID 149]

The objective of this Fund is to provide long-term growth of capital through investment in equity and some debt securities. Investments are primarily in dividend paying equity and fixed income securities of Canadian issuers.

MIDDLEFIELD GLOBAL SUSTAINABLE ENERGY CLASS

[MID 125/127/130] Series F [MID 126]

This Fund seeks to maximize long-term total return by investing in a portfolio of issuers that operate in or have exposure to the sustainable energy sector.

MIDDLEFIELD GLOBAL AGRICULTURE CLASS

[MID 161/163/166] Series F [MID 162]

The objective of this Fund is to provide long-term growth of capital by investing in equity securities of issuers operating in the agricultural sector.

MIDDLEFIELD HIGH INTEREST INCOME CLASS

[MID 400/424/425]

The objective of this Fund is to provide a high level of interest income by investing in high quality fixed income securities, while emphasizing capital preservation and liquidity.

All mutual funds are RRSP, RRIF, DPSP, RESP, RDSP and TFSA eligible. The Fund codes are listed in brackets after each fund name.

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE YEAR ENDED DECEMBER 31, 2021

This annual management report of fund performance contains financial highlights and should be read in conjunction with the complete audited annual financial statements of the investment fund that follow this report.

Unitholders may contact us by calling 1-888-890-1868, by writing to us at Middlefield Group at one of the addresses on the back cover or by visiting our website at www.middlefield.com to request a copy of the investment fund's annual financial statements, proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure.

Management's Discussion of Fund Performance

Investment Objectives and Strategies

Global Healthcare Dividend Fund (the "Fund") is a mutual fund trust. The Fund is authorized to issue series of units designated as Series A and F. The investment objectives of the Fund are to provide holders of units with: (i) stable cash distributions; and (ii) long-term total return through distributions and capital appreciation of the Fund's investment portfolio. The Fund's investment strategy focuses on investing in dividend paying securities of global issuers that derive a significant portion of their revenue or earnings from products or services related to healthcare.

Risk

The Fund is exposed to several risks that may affect its performance. The overall risk of the Fund is as described in its prospectus dated July 12, 2021. During the past year, the overall risk level of the Fund may have been impacted as follows:

Market Risk

Market risk describes the Fund's exposure to volatility in the market value of its underlying securities. Equity markets continue to exhibit volatility due to high levels of inflation, supply chain bottlenecks, labour shortages, as well as the uncertain recovery from the Coronavirus outbreak. The Fund seeks to mitigate risk through active management and diversification.

Results of Operations

Investment Performance

The net assets of the Fund increased from \$82.7 million at December 31, 2020 to \$94.4 million at December 31, 2021. Net assets on a per unit basis for Series A increased from \$14.23 at December 31, 2020 to \$16.20 at December 31, 2021. Net assets on a per unit basis for Series F increased from \$14.92 at December 31, 2020 to \$17.21 at December 31, 2021. The Fund recorded a \$15.3 million net gain on its investment portfolio during the year ended December 31, 2021.

Revenue and Expenses

Revenue for the year ended December 31, 2021 amounted to \$16.5 million, up from \$7.9 million in 2020. The increase was primarily due to the higher net gain on

the Fund's investments. Operating expenses for the year remained unchanged from the prior year at approximately \$1.9 million. The management expense ratio ("MER") in 2021 was 2.56% for Series A and 1.46% for Series F. Distributions for the year ended December 31, 2021 amounted to \$0.48 per unit for both Series A and Series F.

Trends

Past headwinds for the biopharma industry, including drug pricing, regulatory uncertainty and lack of M&A, are gradually turning into tailwinds. The healthcare sector finished the year trading at a forward P/E multiple of just 17.3x, more than 4 turns cheaper than the S&P 500 multiple of 21.6x.

Related Party Transactions

Pursuant to a management agreement, Middlefield Limited (the "Manager") receives a management fee. For further details please see the "Management Fees" section of this report. Middlefield Capital Corporation ("MCC" or the "Advisor"), the advisor to the Fund and a company under common control with the Manager, receives advisory fees from the Manager out of the management fee. MCC also receives brokerage commissions from the Fund in connection with securities transactions. All brokerage commissions paid by the Fund to MCC were at or below market rates. For further details please see the notes to the financial statements.

Management Fees

Management fees are calculated at 2.0% per annum for the Series A units and 1.0% per annum for the Series F units, of the net asset value of each Series and are split between the Manager, the Advisor and investment dealers who receive trailing commissions. The Manager receives fees for the general administration of the Fund, including maintaining the accounting records, executing securities trades, monitoring compliance with regulatory requirements, and negotiating contractual agreements, among other things. The Advisor receives fees from the Manager for providing investment advice in respect of the portfolio in accordance with the investment objectives and strategies of the Fund.

Financial Highlights

Net Assets Attributable to Holders of Redeemable Units are calculated in accordance with International Financial Reporting Standards ("IFRS").

"Net Asset Value" is calculated in accordance with section 14.2 of National Instrument 81-106 "Investment Fund Continuous Disclosure" ("NI 81-106") and is used for transactional pricing purposes.

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the indicated periods. Ratios and Supplemental Data are derived from the Fund's Net Asset Value.

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE YEAR ENDED DECEMBER 31, 2021

The Fund's Net Assets Per Unit ⁽¹⁾ – Series A

	2021	2020	2019	2018	2017
Net Assets Attributable to Holders of Redeemable Units, Beginning of Year	\$ 14.23	\$ 13.73	\$ 12.71	\$ 11.74	\$ 11.16
INCREASE (DECREASE) FROM OPERATIONS:					
Total Revenue	0.19	0.17	0.21	0.20	0.19
Total Expenses (excluding distributions)	(0.38)	(0.37)	(0.34)	(0.33)	(0.29)
Realized Gains (Losses) for the Year	0.70	1.43	0.33	1.05	1.14
Unrealized Gains (Losses) for the Year	1.93	(0.26)	1.25	0.44	0.08
Transaction Costs on Purchase and Sale of Investments	-	(0.02)	(0.01)	(0.01)	(0.02)
TOTAL INCREASE (DECREASE) FROM OPERATIONS ⁽²⁾	2.45	0.98	1.46	1.29	0.90
DISTRIBUTIONS:					
From Net Investment Income	-	-	-	-	-
From Capital Gains	0.48	0.48	0.33	0.32	0.32
Return of Capital	-	-	0.11	-	-
TOTAL DISTRIBUTIONS ⁽³⁾	0.48	0.48	0.44	0.32	0.32
Net Assets Attributable to Holders of Redeemable Units, End of Year	\$ 16.20	\$ 14.23	\$ 13.73	\$ 12.71	\$ 11.74

The Fund's Net Assets per Unit⁽¹⁾ – Series F

	2021	2020	2019	2018	2017 ⁽⁴⁾
Net Assets Attributable to Holders of Redeemable Units, Beginning of Year	\$ 14.92	\$ 14.22	\$ 13.00	\$ 11.87	\$ 11.15
INCREASE (DECREASE) FROM OPERATIONS:					
Total Revenue	0.20	0.18	0.21	0.23	0.24
Total Expenses (excluding distributions)	(0.23)	(0.22)	(0.20)	(0.20)	(0.26)
Realized Gains (Losses) for the Year	0.75	1.48	0.35	1.01	3.68
Unrealized Gains (Losses) for the Year	2.06	(0.33)	1.31	0.37	(2.97)
Transaction Costs on Purchase and Sale of Investments	-	(0.01)	-	(0.01)	(0.02)
TOTAL INCREASE (DECREASE) FROM OPERATIONS⁽²⁾	2.77	1.18	1.66	1.45	1.04
DISTRIBUTIONS:					
From Net Investment Income	-	-	0.02	0.02	-
From Capital Gains	0.48	0.48	0.42	0.30	0.32
TOTAL DISTRIBUTIONS⁽³⁾	0.48	0.48	0.44	0.32	0.32
Net Assets Attributable to Holders of Redeemable Units, End of Year	\$ 17.21	\$ 14.92	\$ 14.22	\$ 13.00	\$ 11.87

⁽¹⁾ This information is derived from the Fund's audited annual financial statements.

⁽²⁾ Net Assets Attributable to Holders of Redeemable Units and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of units outstanding over the financial year. This schedule is not a reconciliation of Net Asset Value since it does not reflect unitholder transactions as shown on the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units and accordingly columns may not add.

⁽³⁾ Distributions were paid in cash/reinvested in additional units of the Fund, or both.

⁽⁴⁾ The Fund was converted into an open-end mutual fund trust on December 20, 2016. Series F units were first distributed on January 12, 2017. Until then, Series F units shared the same value as Series A units.

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE YEAR ENDED DECEMBER 31, 2021

Ratios and Supplemental Data – Series A

	2021	2020	2019	2018	2017
Total Net Asset Value (000s) ⁽¹⁾	\$ 61,559	\$ 55,638	\$ 56,998	\$ 59,263	\$ 64,826
Number of Units Outstanding ⁽¹⁾	3,798,979	3,909,401	4,151,660	4,662,829	5,521,831
Management Expense Ratio ("MER") ⁽²⁾	2.56%	2.62%	2.62%	2.62%	2.54%
MER (excluding interest expense and issuance costs) ⁽²⁾	2.56%	-	-	-	-
Trading Expense Ratio ⁽³⁾	0.01%	0.10%	0.04%	0.09%	0.15%
Portfolio Turnover Rate ⁽⁴⁾	13.11%	42.96%	26.72%	20.63%	48.83%
Net Asset Value Per Unit	\$ 16.20	\$ 14.23	\$ 13.73	\$ 12.71	\$ 11.74

Ratios and Supplemental Data – Series F

	2021	2020	2019	2018	2017 ⁽⁵⁾
Total Net Asset Value (000s) ⁽¹⁾	\$ 32,814	\$ 27,086	\$ 24,672	\$ 18,501	\$ 15,917
Number of Units Outstanding ⁽¹⁾	1,906,887	1,815,020	1,735,216	1,422,706	1,340,539
Management Expense Ratio ("MER") ⁽²⁾	1.46%	1.52%	1.50%	1.52%	1.47%
Trading Expense Ratio ⁽³⁾	0.01%	0.10%	0.04%	0.09%	0.15%
Portfolio Turnover Rate ⁽⁴⁾	13.11%	42.96%	26.72%	20.63%	48.83%
Net Asset Value per Unit	\$ 17.21	\$ 14.92	\$ 14.22	\$ 13.00	\$ 11.87

⁽¹⁾ This information is provided as at December 31 of the year shown.

⁽²⁾ The MER is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average Net Asset Value during the year. The MER excluding interest expense and issuance costs has been presented separately as it expresses only the ongoing management and administrative expenses of the Fund as a percentage of average Net Asset Value. Issuance costs are one-time costs incurred at inception, and the inclusion of interest expense does not consider the additional revenues that have been generated from the investment of the leverage in income-generating assets.

⁽³⁾ The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average Net Asset Value during the year.

⁽⁴⁾ The Fund's portfolio turnover rate indicates how actively the Fund's portfolio investments are managed. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher the Fund's portfolio turnover rate in a year, the greater the trading costs payable by the Fund in the year, and the greater the chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high turnover rate and the performance of a fund.

⁽⁵⁾ The Fund was converted into an open-end mutual fund trust on December 20, 2016. Series F units were first distributed on January 12, 2017. Until then, Series F units shared the same value as Series A units.

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE



FOR THE YEAR ENDED DECEMBER 31, 2021

Past Performance

The performance information shown, which is based on Net Asset Value, assumes that all distributions paid by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

Year-By-Year Returns

The bar chart shows how the Fund's performance has varied from year to year for each of the years shown. The return for 2014 is not presented since it relates to a partial period. The charts indicate, in percentage terms, how much an investment made the first day of each financial year would have grown or decreased by the last day of the financial year.



ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE YEAR ENDED DECEMBER 31, 2021

Annual Compound Returns

	Periods Ended December 31, 2021				Since Inception
	One Year	Three Years	Five Years		
Global Healthcare Dividend Fund – Series A	17.62%	12.12%	11.07%		11.55%
MSCI Daily Total Return World Net Healthcare USD Index	18.69%	15.88%	14.12%		13.14%

	Periods Ended December 31, 2021				Since Inception
	One Year	Three Years	Five Years		
Global Healthcare Dividend Fund – Series F	18.97%	13.39%	12.32%		12.41%
MSCI Daily Total Return World Net Healthcare USD Index	18.69%	15.88%	14.12%		13.14%

The MSCI Daily Total Return World Net Healthcare USD Index (the “Index”) is designed to capture the large and mid-cap segments across 23 Developed market countries. All securities in the index are classified in the Healthcare sector as per the Global Industry Classification Standard.

The Fund’s total return in 2021 was in line with the return generated by the Index. The Fund’s performance in 2021 was influenced by the Fund’s focus on dividend paying securities.

ANNUAL MANAGEMENT REPORT OF FUND PERFORMANCE

FOR THE YEAR ENDED DECEMBER 31, 2021

Summary of Investment Portfolio

AS AT DECEMBER 31, 2021

Top Twenty-Five Holdings

DESCRIPTION	% OF NET ASSET VALUE
1 Thermo Fisher Scientific Inc.	4.9
2 Pfizer Inc.	4.7
3 UnitedHealth Group Inc.	4.7
4 Danaher Corp.	4.6
5 Eli Lilly and Company	4.4
6 Roche Holding AG	3.9
7 DexCom Inc.	3.6
8 Zoetis Inc.	3.6
9 CVS Health Corp.	3.5
10 Johnson & Johnson	3.4
11 Vertex Pharmaceuticals Inc.	3.2
12 IQVIA Holdings Inc.	3.0
13 Regeneron Pharmaceuticals Inc.	3.0
14 Intuitive Surgical Inc.	2.9
15 Abbott Laboratories	2.8
16 Abbvie Inc.	2.7
17 Becton Dickinson and Co.	2.7
18 McKesson Corp.	2.7
19 Stryker Corp.	2.5
20 Bristol-Myers Squibb Co.	2.5
21 Sanofi S.A.	2.4
22 AstraZeneca plc	2.4
23 Centene Corp.	2.2
24 Edwards Lifesciences Corp.	2.1
25 Moderna Inc.	2.0

"Top Twenty-Five Holdings" excludes any temporary cash investments.

ASSET CLASS	% OF NET ASSET VALUE
Healthcare	93.2
Real Estate	3.1
Cash and Short-Term Investments	3.9
Other Assets (Liabilities)	(0.2)
	100.0

TOTAL NET ASSET VALUE	\$ 94,372,121
-----------------------	---------------

The Summary of Investment Portfolio may change over time due to ongoing portfolio transactions.
Please visit www.middlefield.com for the most recent quarter-end Summary of Investment Portfolio.

MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING

The financial statements of Global Healthcare Dividend Fund (the "Fund") have been prepared by Middlefield Limited (the "Manager"), the manager of Fund and approved by the Board of Directors. The Manager is responsible for the information and representations contained in these financial statements and other financial information contained in this report. The Manager maintains appropriate procedures to ensure that relevant and reliable financial information is produced. The financial statements have been prepared in accordance with International Financial Reporting Standards and include certain amounts that are based on estimates and judgments. The significant

accounting policies applicable to the Fund are described in the notes to the financial statements. The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and has reviewed and approved these financial statements.

Deloitte LLP is the external auditor of the Fund. They have audited the financial statements of the Fund in accordance with Canadian generally accepted auditing standards to enable them to express to unitholders their opinion on the financial statements.



Jeremy Brasseur
Director



Craig Rogers
Director

INDEPENDENT AUDITOR'S REPORT

To the Unitholders of Global Healthcare Dividend Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise the statements of financial position as at December 31, 2021 and 2020, and the statements of comprehensive income, changes in net assets attributable to holders of redeemable units and cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at December 31, 2021 and 2020, and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards ("IFRS").

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards ("Canadian GAAS"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. The other information comprises the Management Report of Fund Performance.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We obtained the Management Report of Fund Performance prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in this auditor's report. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue

as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Fund's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian GAAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian GAAS, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the

purpose of expressing an opinion on the effectiveness of the Fund's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants
Licensed Public Accountants
Toronto, Ontario
March 24, 2022

FINANCIAL STATEMENTS


Statements of Financial Position

AS AT DECEMBER 31
(In Canadian Dollars)

	2021	2020
ASSETS		
Current Assets		
Investments at Fair Value Through Profit or Loss	\$ 90,850,694	\$ 78,830,896
Cash	3,692,083	4,018,414
Income and Interest Receivable	53,062	69,126
Prepaid Expenses	20,286	16,896
Subscriptions Receivable	2,958	23,231
Total Assets	94,619,083	82,958,563
LIABILITIES		
Current Liabilities		
Management Fee Payable (Note 7)	143,910	215,743
Accounts Payable and Accrued Liabilities	76,709	15,740
Redemptions Payable	26,343	3,420
Total Liabilities (Excluding Net Assets Attributable to Holders of Redeemable Units)	246,962	234,903
Net Assets Attributable to Holders of Redeemable Units	\$ 94,372,121	\$ 82,723,660
Net Assets Attributable to Holders of Redeemable Units – Series A	\$ 61,558,500	\$ 55,638,036
Net Assets Attributable to Holders of Redeemable Units – Series F	\$ 32,813,621	\$ 27,085,624
Mutual Fund Units Issued and Outstanding – Series A (Note 8)	3,798,979	3,909,401
Mutual Fund Units Issued and Outstanding – Series F (Note 8)	1,906,887	1,815,020
Net Assets Attributable to Holders of Redeemable Units per Unit – Series A	\$ 16.20	\$ 14.23
Net Assets Attributable to Holders of Redeemable Units per Unit – Series F	\$ 17.21	\$ 14.92

The accompanying notes to financial statements are an integral part of these financial statements.

Approved by the Board of Directors of Middlefield Limited, as Manager:


Director: Jeremy Brasseur


Director: Craig Rogers

FINANCIAL STATEMENTS

Statements of Comprehensive Income

FOR THE YEARS ENDED DECEMBER 31
(In Canadian Dollars)

	2021	2020
REVENUE (LOSS)		
Income from Investments	\$ 1,232,152	\$ 1,247,679
Interest Income for Distribution Purposes	2,139	24,492
Securities Lending Income (Note 11)	-	2,508
Foreign Exchange Gain (Loss) on Cash	(458,407)	(135,008)
Other Changes in Fair Value of Financial Assets and Financial Liabilities at Fair Value Through Profit or Loss		
Net Realized Gain (Loss) from Investment Transactions	4,565,162	8,348,141
Change in Net Unrealized Gain (Loss) on Investments	10,869,501	(1,294,692)
Change in Net Unrealized Gain (Loss) on Foreign Currency Transactions	334,476	(312,638)
Total Revenue (Loss)	16,545,023	7,880,482
OPERATING EXPENSES (Note 7)		
Advisory Fee	33,526	36,809
Audit Fees	31,290	30,166
Custodial Fees	9,037	8,588
Fund Administration Costs	139,101	144,979
Independent Review Committee Fees and Expenses	16,702	45,737
Legal Fees	12,345	13,199
Management Fee	1,557,536	1,497,115
Transaction Costs (Note 9)	10,529	69,459
Unitholder Reporting Costs	69,134	78,174
Total Operating Expenses	1,879,200	1,924,226
Profit (Loss) before Tax	14,665,823	5,956,256
Withholding Taxes	139,948	288,563
Profit (Loss) after Tax	\$ 14,525,875	\$ 5,667,693
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Series A	\$ 9,327,864	\$ 3,766,516
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units – Series F	\$ 5,198,011	\$ 1,901,177
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit – Series A (Note 8)	\$ 2.44	\$ 0.95
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit – Series F (Note 8)	\$ 2.78	\$ 1.10

The accompanying notes to financial statements are an integral part of these financial statements.

FINANCIAL STATEMENTS

Statement of Changes in Net Assets Attributable to Holders of Redeemable Units

FOR THE YEAR ENDED DECEMBER 31, 2021

(In Canadian Dollars)

	Series A	Series F	Total
Net Assets Attributable to Holders of Redeemable Units at Beginning of Year	\$ 55,638,036	\$ 27,085,624	\$ 82,723,660
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	9,327,864	5,198,011	14,525,875
DISTRIBUTIONS TO UNITHOLDERS:			
From Capital Gains	(1,826,564)	(898,297)	(2,724,861)
	(1,826,564)	(898,297)	(2,724,861)
REDEEMABLE UNIT TRANSACTIONS:			
Proceeds from Issue of Units	4,123,843	3,920,714	8,044,557
Reinvested Distributions	1,600,514	631,117	2,231,631
Payment on Redemption of Units	(7,305,193)	(3,123,548)	(10,428,741)
	(1,580,836)	1,428,283	(152,553)
Net Assets Attributable to Holders of Redeemable Units at End of Year	\$ 61,558,500	\$ 32,813,621	\$ 94,372,121

Statement of Changes in Net Assets Attributable to Holders of Redeemable Units

FOR THE YEAR ENDED DECEMBER 31, 2020

(In Canadian Dollars)

	Series A	Series F	Total
Net Assets Attributable to Holders of Redeemable Units at Beginning of Year	\$ 56,998,477	\$ 24,671,997	\$ 81,670,474
Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	3,766,516	1,901,177	5,667,693
DISTRIBUTIONS TO UNITHOLDERS:			
From Capital Gains	(1,894,431)	(833,855)	(2,728,286)
	(1,894,431)	(833,855)	(2,728,286)
REDEEMABLE UNIT TRANSACTIONS:			
Proceeds from Issue of Units	4,983,661	5,601,798	10,585,459
Reinvested Distributions	1,669,608	582,033	2,251,641
Payment on Redemption of Units	(9,885,795)	(4,837,526)	(14,723,321)
	(3,232,526)	1,346,305	(1,886,221)
Net Assets Attributable to Holders of Redeemable Units at End of Year	\$ 55,638,036	\$ 27,085,624	\$ 82,723,660

The accompanying notes to financial statements are an integral part of these financial statements.

FINANCIAL STATEMENTS

Statements of Cash Flows

FOR THE YEARS ENDED DECEMBER 31

(In Canadian Dollars)

2021

2020

CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES

Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units	\$ 14,525,875	\$ 5,667,693
Adjustments:		
Proceeds from Sale of Investments	14,216,950	146,728,878
Purchases of Investments	(10,802,085)	(140,456,349)
Foreign Exchange (Gain) Loss on Cash	123,931	447,646
Net Realized (Gain) Loss from Investment Transactions	(4,565,162)	(8,348,141)
Change in Net Unrealized (Gain) Loss on Investments	(10,869,501)	1,294,692
	2,630,008	5,334,419
Net Change in Non-Cash Working Capital	1,810	21,539
Net Cash from (used in) Operating Activities	2,631,818	5,355,958

CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES

Proceeds from Issue of Units	8,064,830	10,570,592
Payment on Redemption of Units	(10,405,818)	(14,720,311)
Distributions Paid	(493,230)	(476,645)
Net Cash from (used in) Financing Activities	(2,834,218)	(4,626,364)
Net Increase (Decrease) in Cash	(202,400)	729,594
Foreign Exchange Gain (Loss) on Cash	(123,931)	(447,646)
Cash at Beginning of Year	4,018,414	3,736,466

Cash at End of Year	\$ 3,692,083	\$ 4,018,414
---------------------	--------------	--------------

The accompanying notes to financial statements are an integral part of these financial statements.

FINANCIAL STATEMENTS

Schedule of Investment Portfolio

AS AT DECEMBER 31, 2021

(In Canadian Dollars)

Description	No. of Securities	Average Cost	Fair Value
Abbott Laboratories	15,000	\$ 1,728,912	\$ 2,666,641
Abbvie Inc.	15,000	1,927,995	2,565,463
Amgen Inc.	5,000	1,102,261	1,420,857
AstraZeneca PLC	15,000	1,361,455	2,227,032
Becton Dickinson and Co.	8,000	1,566,126	2,541,261
Boston Scientific Corp.	30,000	1,521,139	1,609,762
Bristol-Myers Squibb Co.	30,000	2,105,089	2,362,727
Centene Corp.	20,000	1,757,918	2,081,675
CRISPR Therapeutics AG	12,000	781,135	1,148,660
CVS Health Corp.	25,000	2,351,177	3,257,670
Danaher Corp.	10,500	2,042,497	4,363,693
DexCom Inc.	5,000	2,203,244	3,391,249
Edwards Lifesciences Corp.	12,000	1,417,162	1,963,697
Eli Lilly and Company	12,000	3,198,286	4,186,896
Gilead Sciences Inc.	15,000	1,312,401	1,375,763
GlaxoSmithKline plc	60,000	1,546,788	1,649,204
Humana Inc.	2,000	1,167,657	1,171,852
Intuitive Surgical Inc.	6,000	1,192,278	2,723,104
IQVIA Holdings Inc.	8,000	1,105,941	2,851,087
Johnson & Johnson	15,000	1,877,142	3,241,313
McKesson Corp.	8,000	1,806,442	2,511,855
Medtronic plc	12,000	1,177,194	1,568,078
Merck & Co Inc.	15,000	915,226	1,452,120
Moderna Inc.	6,000	489,884	1,924,893
Pfizer Inc.	60,000	2,944,941	4,475,351
Regeneron Pharmaceuticals Inc.	3,500	1,768,962	2,791,971
Roche Holding AG	7,000	2,258,740	3,678,899
Sanofi S.A.	18,000	1,921,984	2,290,336
Stryker Corp.	7,000	1,578,781	2,364,546
Teladoc Health Inc.	5,000	1,065,187	579,913
Thermo Fisher Scientific Inc.	5,500	1,145,090	4,635,543
UnitedHealth Group Inc.	7,000	1,042,445	4,439,956
Vertex Pharmaceuticals Inc.	11,000	1,850,981	3,051,271
Zoetis Inc.	11,000	1,507,094	3,390,718
HEALTHCARE: 93.0%		54,739,554	87,955,056
Healthpeak Properties Inc.	35,000	1,663,913	1,595,551
Welltower Inc.	12,000	963,842	1,300,087
REAL ESTATE: 3.1%		2,627,755	2,895,638
TRANSACTION COSTS (NOTE 9)		(58,630)	-
TOTAL INVESTMENTS: 96.1%		57,308,679	90,850,694
CASH: 3.9%		3,692,083	3,692,083
Total Investment Portfolio, including Cash		\$ 61,000,762	\$ 94,542,777

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

1. Global Healthcare Dividend Fund

Global Healthcare Dividend Fund (the “Fund”) is an unincorporated open-ended investment trust established by Middlefield Limited, a corporation existing under the laws of the Province of Alberta, pursuant to a supplemental declaration of trust dated December 22, 2016. From September 24, 2014 until December 20, 2016, the Fund operated as a closed-end investment trust established under the laws of the Province of Alberta. The Fund was listed on the Toronto Stock Exchange and effectively commenced operations on October 23, 2014, when it first issued units through an initial public offering. As part of the process of converting to an open-ended unit trust, the Fund was delisted from the Toronto Stock Exchange on December 19, 2016. The Fund is authorized to issue series of units designated as Series A and Series F. Each series has a different management fee rate. Middlefield Limited, a company incorporated in Alberta, is both the manager and trustee of the Fund (the “Manager”) and Middlefield Capital Corporation (“MCC”), a company under common control with the Manager, is the advisor to the Fund (the “Advisor”). The address of the Fund’s registered office is 812 Memorial Drive N.W., Calgary, Alberta. These financial statements, expressed in Canadian Dollars, were authorized for issuance by the board of directors of the Manager on March 24, 2022.

2. Basis of Presentation

These financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as published by the International Accounting Standards Board (“IASB”) and as required by Canadian securities legislation and the Canadian Accounting Standards Board.

3. Summary of Significant Accounting Policies

A. Basis of Accounting

IFRS 9 *Financial Instruments* (“IFRS9”)

The Fund classifies and measures financial instruments in accordance with IFRS 9, which requires assets to be carried at amortized cost or fair value, with changes in fair value recognized in profit and loss or other comprehensive income, based on the entity’s business model for managing financial assets and the contractual cash flow characteristics of the financial assets. The Fund’s financial assets and liabilities are classified at fair value through profit or loss (“FVTPL”) and amortized cost.

Classification, Measurement, Impairment and Hedge Accounting

The Fund classifies its investments in debt and equity securities based on its business model for managing those financial assets and the contractual cash flow characteristics of the financial assets. These financial assets are managed and their performance is evaluated on a fair value basis. The Fund also manages these financial assets with the objective of realizing cash flows through sales. Further, an option to irrevocably designate any equity securities at fair value through other comprehensive income (“FVOCI”) was chosen upon adoption. Consequently, these financial assets are mandatorily measured at FVTPL.

Financial assets or financial liabilities held for trading are those acquired principally for the purpose of selling or repurchasing in the near future or on initial recognition they are a part of a portfolio of identified financial instruments that the Fund manages together and has a recent actual pattern of short term profit taking. All derivatives and short positions are included in this category and mandatorily measured at FVTPL. The financial assets and liabilities measured at amortized cost include cash collateral posted on derivative positions, accrued income, due to and from brokers and other short term receivables and payables.

IFRS 9 uses the expected credit loss model (“ECL”), as the new impairment model for financial assets carried at amortized cost. The Fund’s financial assets measured at amortized cost consist of trade receivables with no financing component and which have maturities of less than 12 months, as such, it has chosen to apply the simplified ECL approach, whereby any loss allowance is recognized based on the lifetime of ECLs. Due to the high quality and short-term nature of the trade receivables, there are no expected credit losses associated with them and they are not considered impaired at the reporting dates.

The Fund does not apply general hedge accounting to any of its derivatives positions.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

3. Summary of Significant Accounting Policies (continued)

B. Financial Instruments

The Fund's financial instruments may include: short-term investments, fixed income, equities, structured products, derivatives (collectively referred to as "investments"), cash, accounts receivable – portfolio securities sold, income and interest receivable, accounts receivable, subscriptions receivable, prepaid interest, prepaid expenses, loan payable, accounts payable – portfolio securities purchased, accounts payable and accrued liabilities, redemptions payable and distributions payable. The Fund recognizes financial instruments at fair value upon initial recognition, plus transaction costs in the case of financial instruments measured at amortized cost. Regular way purchases and sales of financial assets are recognized at their trade date. The Fund's investments and derivative assets and liabilities are measured at fair value. The Fund's Net Assets Attributable to Holders of Redeemable Units are measured at fair value. All other financial assets and liabilities are measured at amortized cost. Under this method, financial assets and liabilities reflect the amount required to be received or paid, discounted, when appropriate, at the contract's effective interest rate. The Fund's accounting policies for measuring the fair value of its investments and derivatives are identical to those used in measuring its net asset value ("NAV") for transactions with unitholders.

The Fund only offsets financial assets and financial liabilities if the Fund has a legally enforceable right to offset recognized amounts and either intends to settle on a net basis or to realize the asset and settle the liability simultaneously.

C. Redeemable Units and Net Assets Attributable to Holders of Redeemable Units

The Fund has two series of redeemable units in issue: Series A and Series F. Both rank *pari passu* in all material respects and have the same terms and conditions other than the management fee rate, which is 2.0% for Series A and 1.0% for Series F.

Redeemable units can be put back to the Fund at any time for cash equal to a proportionate share of the Fund's NAV attributable to the unit class. The redeemable units are classified as financial liabilities and are measured at the redemption amounts.

Redeemable units are issued and redeemed based on the Fund's NAV per unit, calculated by dividing the net assets of the Fund, calculated in accordance with the Fund's Simplified Prospectus, by the number of redeemable units in issue. The Fund's Simplified Prospectus requires that investment positions are valued on the basis of the last traded market price for the purpose of determining the trading NAV per unit for subscriptions and redemptions.

The financial assets and liabilities at fair value through profit or loss in the Statements of Financial Position are based on closing prices in accordance with IFRS.

Distributions are declared at the discretion of the Trustee, and are distributed by the Fund. The Trustee has changed its distribution policy of declaring distributions from quarterly to monthly beginning with a monthly distribution effective April 29, 2020. The Trustee intends to distribute any excess income and capital gains annually in December such that the Fund will not have any liability for taxes (other than those that are immediately refundable). Distribution payments may be adjusted without notice at any time as market conditions change. If the Fund does not earn enough income and capital gains to meet the distributions, it may return capital to make up the difference. Distributions to holders of redeemable units are recognized in the Statements of Changes in Net Assets Attributable to Holders of Redeemable Units.

Net assets are calculated for each series of units of the Fund. The net assets of a particular series of units are computed by calculating the value of the series' proportionate share of the assets and liabilities of the Fund common to all series. Management fees directly attributable to a series are charged to that series. Other expenses, investment income and realized and unrealized gains and losses on investments are allocated proportionately to each series based upon the relative net assets of each series.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

3. Summary of Significant Accounting Policies (continued)

D. Fair Value Measurement

The Fund's own credit risk and the credit risk of the counterparty are taken into account in determining the fair value of financial assets and financial liabilities, including derivative instruments. Investments and futures contracts are valued at fair value using the policies described below.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets is based on quoted market prices at the close of trading on the reporting date. The Fund uses the last traded market price for both financial assets and financial liabilities where the last traded price falls within that day's bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, the Manager determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances.

Futures contracts are marked to market each valuation day according to the gain or loss that would have been realized if the contracts had been closed out. Gains or losses arising from futures contracts are recorded as unrealized gain (loss) on futures contracts and shown as an asset (liability) on the Statements of Financial Position until the contracts are closed out or expire, at which time the gains (losses) are realized.

The fair value of financial assets and liabilities that are not traded in an active market (for example, over-the-counter derivatives) is determined by using valuation techniques. The Fund uses a variety of methods and makes assumptions that are based on market conditions existing at each reporting date. Valuation techniques used include the use of comparable recent arm's length transactions, reference to other instruments that are substantially the same, discounted cash flow analysis, option pricing models and other valuation techniques commonly used by market participants making the maximum use of market inputs and relying as little as possible on entity specific inputs.

E. Investment Transactions and Income Recognition

Investment transactions are accounted for as of the trade date and any realized gains or losses from such transactions are calculated on an average cost basis. Average cost does not include amortization of premiums or discounts on fixed income securities with the exception of zero coupon bonds. The change in the difference between fair value and average cost of the investments is recorded as an unrealized gain (loss) on investments. Income from investments is recognized on the ex-dividend or ex-distribution date. Interest income for distribution purposes shown on the Statements of Comprehensive Income represents the interest received on bank deposits by the Fund and, if the Fund holds fixed income investments, coupon interest accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds which are amortized on a straight line basis. The interest income for distribution purposes is the tax basis of calculating the interest received and which is subject to tax. Income distributions received are treated consistently with dividends and interest and recorded in income in the Statements of Comprehensive Income.

F. Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per Unit

Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per unit in the Statements of Comprehensive Income represents the increase (decrease) in Net Assets Attributable to Holders of Redeemable Units for each series divided by the average units outstanding for each series during the year.

G. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and accordingly, is subject to tax on its income, including net realized capital gains in the taxation year, which is not paid or payable to its unitholders as at the end of the taxation year. It is the intention of the Fund to distribute all of its net income and sufficient net realized capital gains so that the Fund will not be subject to income taxes other than foreign withholding taxes, if applicable. Accordingly, no provision for income taxes is required.

The Fund currently incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income and gains are recorded on a gross basis and the related withholding taxes are shown separately in the Statements of Comprehensive Income.

Distributions received from investments in trust units that are treated as a return of capital for tax purposes are used to reduce the average cost of the underlying investments on the Schedule of Investment Portfolio.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

3. Summary of Significant Accounting Policies (continued)

H. Foreign Currency Translation

Foreign currency amounts are translated into Canadian dollars as follows: fair value of investments, forward currency contracts and other assets and liabilities, at the closing rate of exchange on each business day; income and expenses, and purchases, sales and settlements of investments, at the rate of exchange prevailing on the respective dates of such transactions.

I. Critical Accounting Estimates and Judgments

The preparation of financial statements requires management to use judgment in applying its accounting policies and to make estimates and assumptions about the future. The following discusses the most significant accounting judgments and estimates that the Fund has made in preparing the financial statements:

Determination of Functional Currency

'Functional currency' is the currency of the primary economic environment in which the Fund operates. If indicators of the primary economic environment are mixed, then management uses its judgment to determine the functional currency that most faithfully represents the economic effect of the underlying transactions, events, and conditions. The majority of the Fund's investments and transactions are denominated in Canadian dollars. Investor subscriptions and redemptions are also received and paid in Canadian dollars. Accordingly, management has determined that the functional currency of the Fund is Canadian dollars.

Fair Value Measurement of Derivatives and Securities Not Quoted in an Active Market

The Fund may hold financial instruments that are not quoted in active markets, including derivatives. Fair values of such instruments are determined using valuation techniques and may be determined using reputable pricing sources (such as pricing agencies) or indicative prices from market makers. Broker quotes as obtained from the pricing sources may be indicative and not executable or binding. Where no market data is available, the Fund may value positions using its own models, which are usually based on valuation methods and techniques generally recognized as standard within the industry. The models used to determine fair values are validated and periodically reviewed by experienced personnel of the Manager, independent of the party that created them. The models used for private equity securities are based mainly on earnings multiples adjusted for a lack of marketability as appropriate.

Models use observable data, to the extent practicable. However, areas such as credit risk (both own and counterparty), volatilities and correlations require the Manager to make estimates. Changes in assumptions about these factors could affect the reported fair values of financial instruments. The Fund considers observable data to be market data that is readily available, regularly distributed and updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. Refer to Note 4 for further information about the fair value measurement of the Fund's financial instruments.

J. Securities Lending

The Fund may enter into securities lending transactions. These transactions involve the temporary exchange of securities as collateral with a commitment to deliver the same securities on a future date. Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on securities held as collateral. Income earned from these transactions is recognized on an accrual basis and is included in the Statements of Comprehensive Income.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

4. Fair Value Disclosure

The Fund classifies fair value measurements within a hierarchy which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The fair values of the Fund's financial instruments are classified into levels using the following fair value hierarchy:

Level 1	Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
Level 2	Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active.
Level 3	Inputs that are unobservable and where there is little, if any, market activity. Inputs into the determination of fair value require significant management judgement or estimation.

The Fund's investments at fair value as at December 31, 2021 and 2020 trade in active markets and are therefore classified as Level 1.

All fair value measurements are recurring. The carrying values of cash, income and interest receivable, prepaid expenses, subscriptions receivable, management fee payable, accounts payable and accrued liabilities, redemptions payable and the Fund's obligation for Net Assets Attributable to Holders of Redeemable Units approximate their fair values due to their short-term nature.

Fair values are classified as Level 1 when the related security is actively traded and a quoted price is available. If an instrument classified as Level 1 subsequently ceases to be actively traded, it is transferred out of Level 1. In such cases, instruments are reclassified into Level 2, unless the measurement of its fair value requires the use of significant unobservable inputs, in which case it is classified as Level 3.

The Fund's policy is to recognize transfers in and out of the fair value hierarchy levels as at the end of the reporting year for transfers between Levels 1 and 2 and as at the date of the transfer for transfers in and out of Level 3. No transfers between levels have occurred during the years ended December 31, 2021 and 2020.

5. Financial Risk Management

In the normal course of business the Fund is exposed to a variety of financial risks: price risk, liquidity risk, foreign exchange rate risk, credit risk and concentration risk. The Fund's primary risk management objective is to protect earnings and cash flow and, ultimately, unitholder value. Risk management strategies, as discussed below, are designed and implemented to ensure the Fund's risks and related exposures are consistent with its objectives and risk tolerance.

Most of the Fund's risks are derived from its investments. The value of the investments within the Fund's portfolio can fluctuate on a daily basis as a result of changes in interest rates, economic conditions, commodity prices, the market and company news related to specific securities held by the Fund. The investments are made in accordance with the Fund's risk management policies. The policies establish investment objectives, strategies, criteria and restrictions. The objectives of these policies are to identify and mitigate investment risk through a disciplined investment process and the appropriate structuring of each transaction.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

5. Financial Risk Management (continued)

A. Price Risk

Price risk is the risk that changes in the prices of the Fund's investments will affect the Fund's income or the value of its financial instruments. The Fund's price risk is driven primarily by volatility in commodity and equity prices. Rising commodity and equity prices may increase the price of an investment while declining commodity and equity prices may have the opposite effect. The Fund mitigates price risk by making investing decisions based upon various factors, including comprehensive fundamental analysis prepared by industry experts to forecast future commodity and equity price movements. The Fund's market positions are monitored on a daily basis by the portfolio manager and regular financial reviews of publicly available information related to the Fund's investments are performed to ensure that any risks are within established levels of risk tolerance. The Fund is exposed to price risk through the following financial instrument:

	2021	2020
Investments at FVTPL	\$ 90,850,694	\$ 78,830,896

Based on the above exposure at December 31, 2021, a 10% increase or decrease in the prices of the Fund's investments would result in a \$9,085,069 (December 31, 2020 - \$7,883,090) increase or decrease in total equity of the Fund, with all other factors held constant.

B. Liquidity Risk

Liquidity risk is defined as the risk that the Fund may not be able to settle or meet its obligations when due. The Fund is exposed to daily cash redemptions of its units. The units of the Fund are issued and redeemed on demand at the NAV per unit. All other obligations of the Fund are due within one year. Liquidity risk is managed by investing the majority of the Fund's assets in investments that are traded in an active market and can be readily sold. The Fund retains sufficient cash to maintain liquidity and comply with liquidity requirements as outlined by securities legislation and its investment policies.

The Fund may invest in securities that are not traded on a public stock exchange or that may be illiquid. As a result, the Fund may not be able to dispose of these investments in a timely manner. The Fund mitigates this risk through active management, which involves detailed analysis of such private entities to ensure they are financially sound and would be attractive to potential investors if a sale is necessary. The Fund's investment policies and securities legislation limit the amount invested in illiquid securities and these limits are monitored. The Fund did not hold any illiquid securities as at December 31, 2021 and 2020.

The tables below present the Fund's financial liabilities based on the remaining period to the contractual maturity date. The amounts in the tables reflect the contractual undiscounted cash flows.

As at December 31, 2021

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Management Fee Payable	\$ 143,910	\$ -	\$ -	\$ 143,910
Accounts Payable and Accrued Liabilities	76,709	-	-	76,709
Redemptions Payable	26,343	-	-	26,343
Net Assets Attributable to Holders of Redeemable Units	94,372,121	-	-	94,372,121
Total	\$ 94,619,083	\$ -	\$ -	\$ 94,619,083

As at December 31, 2020

Financial Liabilities	Less than 1 Month	1 to 3 Months	3 Months to 1 Year	Total
Management Fee Payable	\$ 215,743	\$ -	\$ -	\$ 215,743
Accounts Payable and Accrued Liabilities	15,740	-	-	15,740
Redemptions Payable	3,420	-	-	3,420
Net Assets Attributable to Holders of Redeemable Units	82,723,660	-	-	82,723,660
Total	\$ 82,958,563	\$ -	\$ -	\$ 82,958,563

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

5. Financial Risk Management (continued)

C. Foreign Exchange Rate Risk

Foreign exchange rate risk describes the impact on the underlying value of financial instruments due to foreign exchange rate movements. The Canadian dollar is the Fund's functional and reporting currency. Foreign investments, commodities, cash, receivables and payables denominated in foreign currencies are affected by changes in the value of the Canadian dollar compared to foreign currencies. As a result, financial assets may depreciate/appreciate in the short-term due to the strengthening/weakening of the Canadian dollar against other currencies, and the reverse would be true for financial liabilities. The Fund's exposure to foreign exchange rate risk relates primarily to its investment in securities, which are denominated in various foreign currencies. The Fund has not hedged its exposure to currency fluctuations; however, it closely monitors relevant foreign exchange currency movements. The Fund is exposed to foreign exchange rate risk through the following financial instruments:

As at December 31, 2021

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	\$ 81,005,223	\$ 10,165	\$ 33,558	\$ 81,048,946
U.K. Pound Sterling	3,876,236	-	19,504	3,895,740
European Euro	2,290,336	-	-	2,290,336
Swiss Franc	3,678,899	-	-	3,678,899
Total	\$ 90,850,694	\$ 10,165	\$ 53,062	\$ 90,913,921

As at December 31, 2020

Currency	Investments at FVTPL	Cash	Income and Interest Receivable	Total Exposure
U.S. Dollar	\$ 67,962,705	\$ 2,716,625	\$ 49,273	\$ 70,728,603
U.K. Pound Sterling	3,315,454	-	19,853	3,335,307
European Euro	2,208,193	-	-	2,208,193
Swiss Franc	3,117,433	-	-	3,117,433
Australian Dollar	2,227,111	-	-	2,227,111
Total	\$ 78,830,896	\$ 2,716,625	\$ 69,126	\$ 81,616,647

Based on the above exposure at December 31, 2021, a 10% increase or decrease in the Canadian dollar against the respective currencies would result in a \$9,091,392 (December 31, 2020 – \$8,161,665) decrease or increase in total equity of the Fund, with all other factors held constant.

D. Credit Risk

Credit risk represents the financial loss that the Fund would experience if a counterparty to a financial instrument failed to meet its obligations to the Fund. The Fund is exposed to credit risk on its debt instruments, derivative assets, cash and cash equivalents and other short term trade receivables. The Fund measures credit risk and lifetime ECLs related to the trade receivables using historical analysis and forward looking information in determining the ECL. The carrying amounts of financial assets represent the maximum credit exposure. All transactions executed by the Fund in listed securities are settled upon delivery using approved brokers. The risk of default is considered minimal, as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase only once the broker has received the securities. The trade will fail if either party fails to meet its obligations. There is no significant credit risk related to the Fund's receivables.

The Fund has established various internal controls to help mitigate credit risk, including prior approval of all investments by the Advisor whose mandate includes conducting financial and other assessments of these investments on a regular basis. The Fund has also implemented policies which ensure that investments can only be made with counterparties that have a minimum acceptable credit rating.

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

5. Financial Risk Management (continued)

E. Concentration Risk

The Fund is exposed to the possible risk inherent in the concentration of the investment portfolio in a small number of industries or investment sectors. The Manager moderates this risk through careful selection of securities in several investment sectors. At December 31, 2021 and 2020, the percentages of the Fund's total equity invested in each investment sector were as follows:

Sector	As a % of Net Assets	
	2021	2020
Healthcare	93.2	92.5
Real Estate	3.1	2.8
Total	96.3	95.3

6. Capital Management

The Fund's capital is its Net Assets Attributable to Holders of Redeemable Units representing unitholders' equity. The Fund's objective when managing capital is to safeguard the Fund's ability to continue as a going concern in order to provide returns for unitholders, maximize unitholder value and maintain financial strength.

The Fund is not subject to any externally imposed capital requirements. The Fund's overall strategy with respect to capital risk management remains unchanged from the year ended December 31, 2020.

7. Management Fee and Operating Expenses

The Manager provides investment and administrative services to the Fund. In consideration for such services the Manager receives a monthly fee in arrears based on each series of units as a percentage of the average daily NAV of the series. The management fee for Series A is 2.0% per annum and for Series F is 1.0% per annum. Common expenses incurred by the Fund are allocated among the series on a pro-rata basis among all units of all series. The Manager is reimbursed for reasonable costs related to maintaining the Fund and preparation and distribution of financial statements and other documents to unitholders. For the year ended December 31, 2021, management fees before the absorption of expenses amounted to \$1.6 million. The Fund is responsible for the payment of all expenses relating to the operation of the Fund and the carrying on of its business.

8. Unitholders' Equity

The capital of the Fund is divided into Series A and Series F with each series having an unlimited number of securities. Changes in issued mutual fund units of the Fund are summarized as follows:

	Number of Units – Series A	
	2021	2020
Units Outstanding at Beginning of Year	3,909,401	4,151,660
Units Issued	280,578	351,800
Reinvested Distributions	108,883	119,381
Total	389,461	471,181
Units Redeemed	(499,883)	(713,440)
Net Increase (Decrease)	(110,422)	(242,259)
Units Outstanding at End of Year	3,798,979	3,909,401

	Number of Units – Series F	
	2021	2020
Units Outstanding at Beginning of Year	1,815,020	1,735,216
Units Issued	254,371	386,102
Reinvested Distributions	40,639	39,893
Total	295,010	425,995
Units Redeemed	(203,143)	(346,191)
Net Increase (Decrease)	91,867	(79,804)
Units Outstanding at End of Year	1,906,887	1,815,020

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

8. Unitholders' Equity (continued)

The average number of Series A and Series F units outstanding during the year ended December 31, 2021 were 3,817,651 and 1,869,216 (December 31, 2020 - 3,958,677 and 1,730,456), respectively. These numbers were used to calculate the respective Increase (Decrease) in Net Assets Attributable to Holders of Redeemable Units per unit.

9. Transaction Costs

Brokerage commissions and other transaction costs paid in connection with securities transactions during the year ended December 31, 2021 amounted to \$10,529 (December 31, 2020 – to \$69,459). Included in this amount is \$3,576 (December 31, 2020 – \$31,720) in brokerage commissions that were paid to MCC. All brokerage commissions paid by the Fund to MCC were at or below market rates. Brokerage commissions and other transaction costs are expensed and recorded in the Statements of Comprehensive Income.

10. Loss Carryforwards

At December 31, 2021 the Fund had no non-capital losses (December 31, 2020 - \$nil) and no capital losses (December 31, 2020 - \$nil) available for carryforward tax purposes.

11. Securities Lending

The Fund has entered into a securities lending program with its custodian, RBC Investor Services Trust, in order to earn additional revenue. The aggregate market value of all securities loaned by the Fund will not exceed 50% of the fair value of the assets of the Fund. The Fund will receive collateral of at least 105% of the fair value of the securities on loan. Collateral held is generally comprised of cash and securities of, or guaranteed by, the Government of Canada or a province thereof, or the United States government or its agencies. Securities lending income reported in the Statements of Comprehensive Income is net of a securities lending charge which the Fund's custodian, RBC Investor Services Trust, is entitled to receive.

For the years ended December 31, 2021 and 2020 securities lending income was as follows:

	2021	2020
Gross Securities Lending Income	\$ -	\$ 4,189
Securities Lending Charges	-	(1,466)
Net Securities Lending Income	-	2,723
Withholding Taxes on Securities Lending Income	-	(215)
Net Securities Lending Income Received by the Fund	\$ -	\$ 2,508

There were no securities lending charges during the year ended December 31, 2021. During 2020 these charges represented 35% of the gross securities lending income, all of which was paid to the Fund's custodian.

There were no securities loaned and collateral held as at December 31, 2021 and 2020.

12. Distributions to Unitholders

The Fund pays distributions to unitholders in accordance with its investment objectives. Distributions of the Fund, unless otherwise specified by the unitholder, are automatically reinvested in additional units of the Fund at the NAV without sales charge. Distributions per Series A unit and Series F unit of \$0.48 (December 31, 2020 – \$0.48) were paid to unitholders of the Fund during the year ended December 31, 2021.

Distributions to Unitholders – Series A	2021	2020
From Capital Gains		
Total	\$ 1,826,564	\$ 1,894,431
Per Unit	0.48	0.48

Distributions to Unitholders – Series F	2021	2020
From Capital Gains		
Total	\$ 898,297	\$ 833,855
Per Unit	0.48	0.48

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

13. The outbreak of the novel coronavirus (COVID-19) has led to governments around the world enacting emergency measures that resulted in business disruptions, volatility in markets and a global economic slowdown. The Manager uses judgment in assessing the impact from such events on assumptions and estimates applied in reporting the assets and liabilities in the Fund's financial statements at December 31, 2021. The duration and full extent of impact of the COVID-19 pandemic are unknown at the reporting date and it is therefore not possible to reliably estimate the entire impact on the financial results and position of the Fund in future periods.

MIDDLEFIELD FUNDS FAMILY |

EXCHANGE - TRADED FUNDS (ETFs)	TSX Stock Symbol
• Middlefield Healthcare Dividend ETF (formerly Healthcare & Life Sciences ETF)	MHCD
• Middlefield Health & Wellness ETF	HWF
• Middlefield Innovation Dividend ETF (formerly Global Innovation Dividend Fund)	MINN
• Middlefield Sustainable Global Dividend ETF (formerly Global Dividend growers Income Fund)	MDIV
• Middlefield Sustainable Infrastructure Dividend ETF (formerly Sustainable Infrastructure Dividend Fund)	MINF
• Middlefield Real Estate Dividend ETF (formerly Middlefield REIT INDEXPLUS ETF)	MREL
• Middlefield U.S. Equity Dividend ETF (formerly Middlefield American Core Dividend ETF)	MUSA
TSX-LISTED FUNDS	
• E Split Corp.	ENS ENS.PR.A
• International Clean Power Dividend Fund	CLP.UN
• MBN Corporation	MBN
• Middlefield Global Real Asset Fund	RA.UN
• MINT Income Fund	MID.UN
• Real Estate Split Corp. (formerly Real Estate & E-Commerce Split Corp.)	RS RS.PR.A
• Sustainable Agriculture & Wellness Dividend Fund	AGR.UN
• Sustainable Innovation & Health Dividend Fund	SIH.UN
• Sustainable Real Estate Dividend Fund (commenced March 30, 2022)	MSRE.UN
• Workplace Technology Dividend Fund (commenced November 17, 2021)	WORK.UN
MIDDLEFIELD MUTUAL FUNDS TRUST FUNDS	Fund Code
Series A Units	FE/LL/DSC
• Global Healthcare Dividend Fund	MID 325/327/330
• INDEXPLUS Income Fund	MID 435/437/440
• Middlefield Global Infrastructure Fund	MID 510/519/520
Series F Units	
• Global Healthcare Dividend Fund	MID 326
• INDEXPLUS Income Fund	MID 436
• Middlefield Global Infrastructure Fund	MID 501
MIDDLEFIELD MUTUAL FUNDS CORPORATE CLASS FUNDS	Fund Code
Series A Shares	FE/LL/DSC
• Middlefield Canadian Dividend Growers Class	MID 148/449/450
• Middlefield Global Agriculture Class	MID 161/163/166
• Middlefield Global Dividend Growers Class	MID 181/183/186
• Middlefield Global Real Estate Class	MID 600/649/650
• Middlefield Global Sustainable Energy Class	MID 125/127/130
• Middlefield High Interest Income Class	MID 400/424/425
• Middlefield Income Plus Class	MID 800/849/850
• Middlefield U.S. Dividend Growers Class	MID 710/719/720
Series F Shares	
• Middlefield Canadian Dividend Growers Class	MID 149
• Middlefield Global Agriculture Class	MID 162
• Middlefield Global Dividend Growers Class	MID 182
• Middlefield Global Real Estate Class	MID 601
• Middlefield Global Sustainable Energy Class	MID 126
• Middlefield Income Plus Class	MID 801
• Middlefield U.S. Dividend Growers Class	MID 701
RESOURCE FUNDS	
• Discovery 2021 Short Duration LP (commenced September 22, 2021)	
• MRF 2021 Resource Limited Partnership	
• MRF 2022 Resource Limited Partnership (commenced February 17, 2022)	
INTERNATIONAL FUNDS	
• Middlefield Canadian Income PCC	London UK Stock Exchange (LSE) Symbol:MCT

Dean Orrico
President and Chief Executive Officer

Jeremy T. Brasseur
Executive Chairman

Robert F. Lauzon, CFA
Chief Investment Officer

Independent Review Committee

George S. Dembroski
Former Vice-Chairman
RBC Dominion Securities Limited

H. Roger Garland, CPA, CA
Former Vice-Chairman
Four Seasons Hotels Inc.

Bernard I. Ghert (Chairman)
Former Chairman
Mount Sinai Hospital

Edward V. Jackson
Former Managing Director
RBC Capital Markets

Advisors
Middlefield Capital Corporation
SSR, LLC

Middlefield Group
Polly Tse, CPA, CGA, CPA (IL)
Chief Financial Officer

Craig Rogers, CPA, CGA, CFA
Chief Operating Officer

Mark Aboud
Managing Director,
Workplace Innovation and Productivity

Dennis da Silva
Managing Director, Resource Group

Vincenzo Greco
Managing Director, Trading

Nancy Tham
Managing Director, Sales

Vince Kraljevic, CFA
Executive Director, Corporate Development

Shane Obata, CFA, MFin
Executive Director, Investments

Anthony Tavella, MBA, MFin
Executive Director, International and Marketing

Stacy J. Crestohl
Director, Operations

Rose Espinoza
Director, International

Henry Lee
Director, Sales

Robert Moffat
Director, Investments

Catherine Rebuldela, CPA, CGA
Director, Operations

James Stack
Director, Sales

Mallika Verma
Investment Analyst, Investments

Samantha Drautz
Compliance Officer

Shiranee Gomez
Senior Vice-President

Victor Ngai
Senior Vice-President

Francis Ramirez
Senior Vice-President

Nicole S. Brasseur
Vice-President, Human Resources

Judy Marks
Vice-President, Human Resources

Sarah Roberts, CPA, CMA
Vice-President

Wendy Teo, CPA, CA, CPA (IL)
Vice-President

Jimmy Xu
Vice-President, Information Technology

Sylvia Casillano, CPA, CGA
Assistant Vice-President

Scott Hu
Associate, Information Technology

Ken Lai
Accountant

Stephen Chamberlain
Vice-President,
Middlefield Realty Services Limited

Auditor
Deloitte LLP, Chartered Professional Accountants
RSM Canada LLP

Legal Counsel
Bennett Jones
DLA Piper (Canada) LLP
Fasken Martineau DuMoulin LLP
McCarthy Tétrault

Bankers
Bank of Montreal
Canadian Imperial Bank of Commerce
Royal Bank of Canada
The Bank of Nova Scotia
The Toronto-Dominion Bank

Custodian
RBC Investor Treasury Services

Transfer Agents
RBC Investor Service Trust
Middlefield Capital Corporation

Affiliates
Middlefield Group Limited
Middlefield Capital Corporation
Middlefield Financial Services Limited
MFL Management Limited
MF Properties Limited
Middlefield International Limited
Middlefield Limited
Middlefield Realty Services Limited
Middlefield Resource Corporation

www.middlefield.com
invest@middlefield.com
(888) 890-1868



TORONTO, CANADA
First Canadian Place
58th Floor, P.O. Box 192
Toronto, Ontario
Canada M5X 1A6
Telephone (416) 362-0714
Fax (416) 362-7925

CALGARY, CANADA
812 Memorial Drive NW
Calgary, Alberta
Canada T2N 3C8
Telephone (403) 269-2100
Fax (403) 269-2911

LONDON, ENGLAND
Middlefield International Limited
288 Bishopsgate
London, England
EC2M 4QP
Telephone (0207) 814-6644
Fax (0207) 814-6611

SAN FRANCISCO, USA
Middlefield Financial Services Inc.
50 California Street, Suite 1500,
San Francisco, California
USA 94111
Telephone (415) 835-1308
Fax (415) 835-1350